Gmt Capital Corp Rocket Pharmaceuticals, Inc. Transaction History

Gmt Capital Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.66 - $26.72 $865,654 - $1.12 Million	-41,900 Reduced 18.22%	188,100 $4.05 Million
Q1 2024 May 13, 2024	SELL	$26.16 - $30.74 $2 Million - $2.35 Million	-76,500 Reduced 24.96%	230,000 $6.2 Million
Q4 2023 Feb 12, 2024	SELL	$16.78 - $31.94 $1.76 Million - $3.34 Million	-104,700 Reduced 25.46%	306,500 $9.19 Million
Q3 2023 Nov 13, 2023	SELL	$15.07 - $24.05 $314,963 - $502,645	-20,900 Reduced 4.84%	411,200 $8.43 Million
Q2 2023 Aug 10, 2023	SELL	$16.59 - $23.6 $1.23 Million - $1.75 Million	-74,000 Reduced 14.62%	432,100 $8.59 Million
Q1 2023 May 09, 2023	BUY	$15.79 - $22.6 $2.13 Million - $3.05 Million	134,800 Added 36.3%	506,100 $8.67 Million
Q3 2022 Nov 10, 2022	SELL	$12.37 - $18.41 $1.55 Million - $2.31 Million	-125,500 Reduced 25.26%	371,300 $5.93 Million
Q2 2022 Aug 10, 2022	BUY	$7.96 - $16.64 $3.95 Million - $8.27 Million	496,800 New	496,800 $6.84 Million

209

93.2M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $987M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.